Last reviewed · How we verify
NCT03549728
Effect of Granulocyte Colony-stimulating Factor on Clinical Pregnancy Rate in Patients With Endometriosis Undergoing In-vitro Fertilization After Recurrent Implantation Failure
Phase 2 trial testing Granulocyte Colony-Stimulating Factor in Recurrent Implantation Failure in 88 participants. Status unknown.
1 October 2018
Quick facts
| Lead sponsor | Amira Magdi Guergues Selim |
|---|---|
| Phase | Phase 2 |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | triple |
| Primary purpose | supportive care |
| Enrollment | 88 |
| Start date | 1 June 2018 |
| Primary completion | 1 October 2018 |
| Estimated completion | 1 December 2018 |
Drugs / interventions tested
- Granulocyte Colony-Stimulating Factor
- Intrauterine infusion of normal saline
Conditions studied
- Recurrent Implantation Failure — all drugs for Recurrent Implantation Failure →
- Endometriosis — all drugs for Endometriosis →
Sponsor
Amira Magdi Guergues Selim
Who can join
Adults 20 to 40, female only, with Recurrent Implantation Failure or Endometriosis. Patients with the condition only — healthy volunteers not accepted.
What's being measured
Primary outcomes are the specific endpoints the trial is designed to prove or disprove.
-
Clinical pregnancy rate
Time frame: 5-6 weeks from the day of embryo transfer
The primary outcome measure is the clinical pregnancy rate defined as the observation of gestational sac on transvaginal ultrasound examination three weeks after positive serum βhCG.
Sponsor's own description
The aim of this study is to evaluate the effect of granulocyte colony-stimulating factor on clinical pregnancy rate in patients with endometriosis undergoing in-vitro fertilization after recurrent implantation failure.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Granulocyte-colony stimulating factor administration for subfertile women undergoing assisted reproduction.
Kamath MS, Kirubakaran R, Sunkara SK. · · 2020 · cited 32× · PMID 31978254 · DOI 10.1002/14651858.cd013226.pub2
Verify or expand the search:
- PubMed search for NCT03549728
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Granulocyte Colony-Stimulating Factor
Trials testing the same drug.
- NCT06752694 — Ruxolitinib Based GVHD Prophylaxis Regimen Before, During, and After Hematopoietic Cell Transplantation in Older Adult P · Phase 2 · recruiting
- NCT06059391 — CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors for the Prevention of CMV Infection in Patients Unde · Phase 2 · recruiting
- NCT06158828 — Pilot Study of Memory-like Natural Killer (ML NK) Cells After TCRαβ T Cell Depleted Haploidentical Transplant in AML · Phase 1, PHASE2 · recruiting
- NCT06034470 — Combination Chemotherapy (FLAG-Ida) With Pivekimab Sunirine (PVEK [IMGN632]) for the Treatment of Newly Diagnosed Advers · Phase 1 · active not recruiting
- NCT05907499 — Decitabine for Poor Graft Function Post Allo-HSCT · Phase 3 · not yet recruiting
Other recruiting trials for Recurrent Implantation Failure
Currently open trials in the same condition.
- NCT06762626 — Comparing FET Guided by ERA Vs Standard Timing in Patients with Recurrent Implantation Failure · NA · recruiting
- NCT03900780 — Preimplantation Genetic Testing for Aneuploidies in Patients With Recurrent Implantation Failure · NA · recruiting
- NCT05169541 — Association Between Plasma Level of Mannose Binding Lectin and Human Reproduction · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03549728 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Amira Magdi Guergues Selim
- Last refreshed: 26 May 2018
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03549728.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing